June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
BioNTech (BNTX) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: June 22, 2025 (17:21)
Sector: HealthcareThe share price of BioNTech SE (BNTX) now
News Impact Analyzer
Full report
This Week
|
Na | Impact: Na | News: Na |
Previous Week
|
Bullish | Impact: 2.25 | News: 5 (2/2/1) |
Two Weeks Ago
|
Bullish | Impact: 1.13 | News: 3 (1/1/1) |
Three Weeks Ago
|
Bearish | Impact: 5 | News: 1 |
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 1 (1/0/0) |
Previous Week
|
Neutral | Opinions: 1 |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important BNTX news

BioNTech Acquires CureVac in $1.25B Deal to Bolster Vaccine Portfolio


BioNTech Strengthens mRNA Leadership with $1.25B CureVac Acquisition


RFK Jr. Reshapes CDC Vaccine Panel with New Appointments

Historical and forecast chart of BioNTech stock
The chart below shows the historical price of BioNTech stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the BioNTech stock price can be found in the table below.
Long-term forecasts by years.
BioNTech SE Analysts predictions review

BioNTech's recent acquisition of CureVac and its partnership with Bristol-Myers Squibb highlight strategic moves to diversify revenue streams and enhance its oncology pipeline. These initiatives reduce reliance on COVID-19 vaccine sales and improve its competitive positioning in mRNA therapeutics. While the CureVac acquisition offers promising synergies in R&D efficiencies and margin improvements, the Bristol-Myers collaboration faces speculative risks tied to clinical trial outcomes. Macro pressures like rising interest rates and tighter biotech valuations could weigh on near-term sentiment. Overall, medium-to-long-term prospects remain robust due to pipeline diversification and technological innovation, though short-term volatility persists.

BioNTech Expands Cancer Capabilities Through Strategic CureVac Acquisition

The strategic acquisition of CureVac by BioNTech positions the company to enhance its technological capabilities in targeting cancer treatments. This deal brings complementary mRNA technology to BioNTech's pipeline, which has the potential to strengthen its competitive edge in therapeutic innovation. The author underscores the significance of this integration as a near-term catalyst for investor sentiment.
Merging Strategic Synergies to Address Market Needs
The acquisition also signals BioNTech’s commitment to diversifying its oncology portfolio, which could drive revenue growth and long-term operational sustainability. The author highlights that such diversification reduces reliance on COVID-19 vaccine sales, mitigating single-product risk and responding to evolving market demands.
Moreover, potential R&D efficiencies and cost savings from CureVac’s expertise may improve margins and accelerate commercialization timelines. As noted by the author, these operational improvements could further support the stock’s valuation trajectory in the medium term.

BioNTech's Strategic Alliance with Bristol-Myers: Evaluating Growth Potential and Investment Value

The strategic partnership between BioNTech and Bristol-Myers Squibb emphasizes synergistic growth opportunities, particularly in the field of oncology and immunotherapy advancements. The author highlights that this collaboration leverages BioNTech's expertise in mRNA technology and Bristol-Myers' expansive distribution network, a combination aimed at accelerating innovative treatments to market. This factor is likely to bolster investor sentiment around BNTX due to its potential to unlock new revenue streams.
BioNTech's fiscal discipline and recent R&D investments in expanding its therapeutic pipeline are other critical components of its growth narrative. The focus on diversifying its business model beyond COVID-19 vaccines, as argued by the author, reflects a proactive approach to securing sustainable long-term revenue, which could positively influence its stock's valuation over time.
Focusing on Market Differentiation
The article points out that BioNTech's competitive positioning within the high-growth mRNA therapeutics sector remains one of its strongest assets. Compared to its peers, its collaborative framework and robust intellectual property portfolio place it as a leader in an increasingly competitive market. This competitive edge bodes well for its market capitalization growth prospects in the medium to long-term horizon.
The valuation analysis underscores a cautious optimism, as BNTX's current pricing may undervalue its future growth potential, especially as its non-COVID-related initiatives contribute more meaningfully to revenue. While subject to macroeconomic risks and clinical trial outcomes, the alignment of strategic initiatives suggests the stock may be positioned to outperform in the coming quarters.

Is BioNTech Overestimating BNT-327's Commercial Potential Amid Market Hype?

BioNTech's collaboration with Bristol Myers revolves around BNT-327, an experimental oncology asset. The author suggests that while the partnership signals promise in expanding BioNTech's oncology pipeline, investor enthusiasm may prematurely price in speculative success. Given the clinical uncertainties in early-stage drug development, the near-term stock price impact could be disproportionately driven by sentiment rather than fundamentals.
Evaluating Market Expectations and Risks
The valuation surge tied to the BNT-327 deal reflects heightened expectations, but actual revenue realization may take years and is contingent on clinical milestones. The article asserts that an overhyped narrative could make the stock vulnerable to corrections if pipeline developments underperform or regulatory setbacks occur.
Additionally, the competitive oncology landscape complicates BNT-327's commercial success. The author points to numerous existing and emerging therapies targeting similar indications, which could limit BioNTech's market penetration and pricing power, bluntly reducing upside potential for shareholders.
Broader macroeconomic conditions and declining sentiment in biotech investing add external pressures on BioNTech's stock. While oncology remains a high-growth area, rising interest rates and investor preference for profitability over speculative growth could weigh on valuation in the near term.
BioNTech's strategic pivot toward oncology represents a bold diversification from its historical reliance on COVID-19 vaccine revenue streams. This shift positions the company in the burgeoning immunotherapy space, where advancements in personalized cancer medicines could unlock substantial long-term growth. However, the author, **[Author Name]**, emphasizes that such transformations in focus could entail near-term volatility as the company navigates high research and development costs.
The financial viability of BioNTech's oncology ventures is significantly influenced by its strong cash reserves and profitable operations during the pandemic. As highlighted, these factors provide the company with the capacity to invest intensively in clinical trials and partnerships, shielding it from immediate liquidity concerns.
Impact on Long-Term Growth and Stock Valuation
Market sentiment around BioNTech remains cautiously optimistic, supported by its innovative platform technologies and ongoing trial outcomes. While the oncology transition may heighten risk perception in the short term, the author contends that successful product launches could redefine investor confidence and drive future stock appreciation.
A key factor influencing BioNTech SE's outlook is its waning financial performance, as revenue and profitability have significantly declined following the peak of COVID-19 vaccine demand. This suggests that the company's financials are heavily reliant on pandemic-related revenues, raising concerns about the sustainability of earnings in the near term. The continued erosion here could weigh on the stock price further if not counterbalanced by new revenue streams.
Another critical consideration is the uncertainty surrounding the company's product pipeline. Despite its efforts to diversify into oncology and other therapeutics, no highly compelling near-term catalysts have emerged. This lack of visibility into meaningful pipeline contributions adds another layer of risk to the investment thesis.
Pipeline and Market Dynamics: Core Investor Concerns
Additionally, BioNTech faces increased competition in both the mRNA technology space and the broader biopharmaceutical landscape. Rivals are rapidly innovating, which could dilute BioNTech's market share unless it establishes clear differentiation. This highly competitive environment, combined with ongoing macroeconomic uncertainty, can amplify pressure on the stock.
Lastly, valuation concerns may further temper investor sentiment. With the company's forward price-to-earnings and price-to-sales ratios still elevated relative to declining revenue streams, any failure to deliver new growth avenues could justify continued multiple compression in the stock valuation.
BioNTech's recent quarterly earnings reveal a complex financial landscape characterized by revenue volatility due to declining COVID-19 vaccine demand. The performance underscores a key challenge for the company: the need to diversify its revenue streams and reduce dependency on pandemic-related products, which the author views as a pivotal factor for stock valuation in the near term.
Robust progress in the development of mRNA-based treatments and oncology pipelines suggests potential growth drivers in the long term. The author emphasizes this as a major upside, tempered by the high-risk nature of biotech R&D and the extended timelines needed for clinical trial validation and regulatory approval.
Short-Term Headwinds Still Present Opportunities
Operational cost optimization and management's focus on strategic partnerships could provide near-term resilience amidst revenue headwinds. The author identifies partnerships with pharma giants and expansion into adjacent markets as notable efforts to sustain investor confidence during an uncertain post-COVID environment.
Market sentiment remains cautious as the company navigates balancing R&D investment with profitability goals. As the author notes, this financial duress could lead to continued stock price stagnation unless breakthrough developments generate meaningful catalysts.
BioNTech's pivot towards oncology appears to be a calculated move to diversify its revenue streams beyond its highly successful COVID-19 vaccine portfolio. The company's recent investments in cancer therapeutics emphasize long-term innovation, signaling a willingness to accept higher short-term R&D costs for potentially transformative products that could redefine its revenue mix.
Pipeline progression remains a critical indicator for investors, as any updates—both positive and negative—could significantly influence the stock price. The author notes that upcoming clinical trial results for key oncology candidates act as pivotal inflection points that could inject volatility into the stock, underscoring the high-risk, high-reward nature of the company’s strategy.
Broader Industry Dynamics
The competitive landscape in oncology is intensifying, with BioNTech attempting to carve out a niche in immune-oncology therapies. Strategically, its collaboration efforts and proprietary mRNA technology could provide differentiation, but the author points out that maintaining leadership will require continuous execution against well-funded competitors.
Valuation calls into question near-term upside potential, as current stock levels may already reflect optimism around past vaccine performance and the nascent oncology pipeline. However, the author's analysis indicates that execution success on early-stage candidates could unlock significant value, provided operational efficiencies are maintained amidst rising costs.
BioNTech’s current valuation is significantly lower compared to its peers within the biotechnology sector, creating an opportunity for long-term investors. The undervaluation appears to reflect investor concerns about post-COVID-19 revenue declines, but the company’s broad therapeutic pipeline mitigates this risk by diversifying its revenue base.
Pipeline Innovation and Competitive Position
The company’s robust pipeline of mRNA and immunotherapy-based treatments demonstrates strong innovation potential. Notably, advancements in oncology and other infectious diseases highlight its ability to diversify beyond reliance on COVID-19 vaccine revenues, adding to investor confidence in its future growth trajectory.
Meanwhile, its partnership strategy—most prominently with Pfizer—strengthens its global reach and operational capability. This enhances the ability to commercialize new therapies swiftly, further contributing to its competitive advantage, particularly in the precision medicine space.
Macro factors, including fluctuations in vaccine-related demand and evolving regulatory environments, remain potential headwinds. However, the company’s consistent R&D investments and IP portfolio position it well to navigate these challenges, making it an attractive option in the biotech sector even amidst market volatility.
BioNTech's recent removal of a clinical hold on its antibody-drug conjugate (ADC) development program represents a pivotal step forward in expanding its oncology pipeline. This regulatory clearance not only accelerates research timelines but also reinforces investor confidence in the company's capacity to innovate in targeted cancer therapies, particularly given the growing market potential for ADCs.
The company's strategic emphasis on diversifying revenue streams beyond COVID-19 vaccine sales emerges as a key factor for long-term growth resiliency. Despite declining pandemic-related revenues, BioNTech's progress in oncology therapies suggests a proactive approach to addressing market shifts and sustaining investor interest.
Broader Industry Relevance and Impact on Valuation
Additionally, BioNTech's positioning within the broader biotech space remains competitive, as the advancement of its ADC program aligns with favorable industry trends such as increased demand for precision medicine. This development could improve the company's valuation in the near term as investors factor in its potential to capture market share in an emerging high-growth niche.
Macroeconomic factors, however, pose potential headwinds, particularly rising interest rates and economic uncertainty, which could pressure capital-intensive biotech firms like BioNTech. Nonetheless, the ADC progress provides a strong narrative for value creation that may mitigate broader market risks in the short to medium term.
Comprehensive Analysis of BioNTech (BNTX) Stock Market Performance
Our multifaceted analysis of BioNTech's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in BioNTech stock?
- When should I record a loss on BioNTech stock?
- What are analysts' forecasts for BioNTech stock?
- What is the future of BioNTech stock?
We forecast BioNTech stock performance using neural networks based on historical data on BioNTech stocks.
BioNTech SE is a German biotechnology company that develops and manufactures active immunotherapeutic agents for an individual approach to the treatment of serious diseases. The company is investigating messenger RNA (mRNA) -based drugs for use as individualized immunotherapy for cancer, as vaccines against infectious diseases and as protein replacement therapy for rare diseases, as well as developed cell therapy, new antibodies and small molecules, immunomodulators, as options cancer treatment. The company has developed an intravenous mRNA-based human therapeutic drug to bring individualized mRNA-based cancer immunotherapy to clinical trials and establish its own manufacturing process.
BioNTech SE News influencing stock rates

As of now, Panda has combed through 9 news items directly related to BNTX from the last 30 days. Out of these, 3 clearly showcase a bullish trend, while 3 display bearish tendencies, and 3 events are neutral.
The strength of the bullish trend outpaces the bearish sentiments by 1.18 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.
The news analyzed fell within the period from May 30, 2025, to Jun 14, 2025.
RFK Jr.'s CDC Shake-Up Leaves Vaccine Makers Unmoved


RFK Jr. Revamps CDC Vaccine Advisory Panel Amid Conflict of Interest Allegations


Leadership Void at CDC Sparks Public Health Concerns


CDC Advisor Resignation Sparks Uncertainty Over COVID Vaccine Guidance


Bristol Myers Squibb Bets Big on BioNTech with $11.1B Immunotherapy Deal


CDC Revises Child Immunization Guidance Post RFK Jr. COVID Remarks


FDA Recommends JN.1 COVID Shot: Boost for BioNTech’s Vaccine Plans


RFK Jr. Targets Vaccines and Food Chemicals in New Health Report


BioNTech Launches $1.3B UK R&D Partnership Boosting Innovation


FDA Approves Novavax Shot for Seniors: New Competition for COVID Vaccine Market


BioNTech daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun 24 | 111.04 | 106.31 | 113.37 | 6.64 |
Jun 25 | 112.50 | 110.21 | 117.30 | 6.43 |
Jun 26 | 113.92 | 112.42 | 117.27 | 4.32 |
Jun 27 | 110.30 | 106.79 | 112.42 | 5.27 |
Jun 28 | 114.67 | 109.99 | 117.01 | 6.38 |
Jun 29 | 113.84 | 112.27 | 117.05 | 4.26 |
Jun 30 | 116.78 | 111.66 | 120.28 | 7.72 |
Jul 01 | 116.92 | 113.20 | 119.93 | 5.95 |
Jul 02 | 112.29 | 110.13 | 115.66 | 5.02 |
Jul 03 | 108.11 | 105.97 | 110.71 | 4.47 |
Jul 04 | 109.80 | 105.52 | 111.84 | 5.99 |
Jul 05 | 110.92 | 107.72 | 116.17 | 7.85 |
Jul 06 | 115.71 | 110.43 | 120.98 | 9.56 |
Jul 07 | 121.05 | 116.91 | 125.41 | 7.27 |
Jul 08 | 125.48 | 122.77 | 129.40 | 5.40 |
Jul 09 | 123.30 | 118.79 | 125.59 | 5.73 |
Jul 10 | 125.45 | 120.55 | 127.03 | 5.37 |
Jul 11 | 131.69 | 128.22 | 133.59 | 4.19 |
Jul 12 | 132.48 | 127.64 | 137.57 | 7.78 |
Jul 13 | 125.01 | 121.86 | 129.44 | 6.22 |
Jul 14 | 128.69 | 126.76 | 130.31 | 2.80 |
Jul 15 | 126.14 | 121.75 | 129.77 | 6.59 |
Jul 16 | 133.71 | 130.58 | 139.56 | 6.88 |
Jul 17 | 141.01 | 135.00 | 144.65 | 7.14 |
Jul 18 | 146.51 | 140.79 | 148.88 | 5.74 |
Jul 19 | 155.21 | 149.44 | 161.54 | 8.10 |
Jul 20 | 151.58 | 145.67 | 157.49 | 8.12 |
Jul 21 | 146.67 | 143.59 | 152.30 | 6.07 |
Jul 22 | 139.19 | 135.43 | 141.36 | 4.38 |
Jul 23 | 130.84 | 127.93 | 133.66 | 4.48 |
BioNTech Daily Price Targets
BioNTech Stock Forecast 06-24-2025.
Forecast target price for 06-24-2025: $111.04.
Positive dynamics for BioNTech shares will prevail with possible volatility of 6.229%.
Pessimistic target level: 106.31
Optimistic target level: 113.37
BioNTech Stock Forecast 06-25-2025.
Forecast target price for 06-25-2025: $112.50.
Positive dynamics for BioNTech shares will prevail with possible volatility of 6.042%.
Pessimistic target level: 110.21
Optimistic target level: 117.30
BioNTech Stock Forecast 06-26-2025.
Forecast target price for 06-26-2025: $113.92.
Positive dynamics for BioNTech shares will prevail with possible volatility of 4.138%.
Pessimistic target level: 112.42
Optimistic target level: 117.27
BioNTech Stock Forecast 06-27-2025.
Forecast target price for 06-27-2025: $110.30.
Negative dynamics for BioNTech shares will prevail with possible volatility of 5.004%.
Pessimistic target level: 106.79
Optimistic target level: 112.42
BioNTech Stock Forecast 06-28-2025.
Forecast target price for 06-28-2025: $114.67.
Positive dynamics for BioNTech shares will prevail with possible volatility of 5.998%.
Pessimistic target level: 109.99
Optimistic target level: 117.01
BioNTech Stock Forecast 06-29-2025.
Forecast target price for 06-29-2025: $113.84.
Negative dynamics for BioNTech shares will prevail with possible volatility of 4.085%.
Pessimistic target level: 112.27
Optimistic target level: 117.05
BNTX (BNTX) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul. | 111.88 | 107.58 | 119.13 | 9.69 |
Aug. | 108.25 | 103.32 | 110.85 | 6.80 |
Sep. | 107.60 | 100.50 | 117.55 | 14.50 |
Oct. | 110.32 | 103.30 | 113.63 | 9.09 |
Nov. | 112.43 | 108.52 | 121.61 | 10.76 |
Dec. | 109.33 | 104.21 | 119.70 | 12.93 |
BioNTech forecast for this year
BioNTech Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $111.879. Pessimistic: $107.58. Optimistic: $119.13
BioNTech Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $108.254. Pessimistic: $103.32. Optimistic: $110.85
BioNTech Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $107.604. Pessimistic: $100.50. Optimistic: $117.55
BioNTech Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $110.316. Pessimistic: $103.30. Optimistic: $113.63
BioNTech Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $112.434. Pessimistic: $108.52. Optimistic: $121.61
BioNTech Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $109.331. Pessimistic: $104.21. Optimistic: $119.70
BioNTech (BNTX) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 120.35 | 116.74 | 127.86 | 8.70 |
Feb | 122.95 | 120.00 | 126.05 | 4.80 |
Mar | 125.61 | 116.86 | 131.94 | 11.42 |
Apr | 124.40 | 113.65 | 136.34 | 16.64 |
May | 113.06 | 106.54 | 123.50 | 13.73 |
Jun | 107.90 | 101.30 | 118.26 | 14.34 |
Jul | 119.29 | 111.85 | 122.44 | 8.65 |
Aug | 119.15 | 109.71 | 128.02 | 14.30 |
Sep | 121.73 | 112.08 | 125.52 | 10.71 |
Oct | 125.08 | 114.88 | 134.54 | 14.62 |
Nov | 137.09 | 132.49 | 146.80 | 9.75 |
Dec | 140.88 | 132.76 | 149.16 | 10.99 |
BioNTech (BNTX) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 140.37 | 131.44 | 147.11 | 10.65 |
Feb | 134.64 | 126.73 | 141.43 | 10.40 |
Mar | 129.96 | 126.21 | 141.19 | 10.60 |
Apr | 125.12 | 115.06 | 137.13 | 16.10 |
May | 131.43 | 120.86 | 139.79 | 13.54 |
Jun | 136.95 | 127.09 | 147.47 | 13.82 |
Jul | 153.22 | 148.25 | 164.80 | 10.04 |
Aug | 163.51 | 152.13 | 169.20 | 10.09 |
Sep | 183.14 | 171.49 | 187.97 | 8.77 |
Oct | 161.16 | 148.78 | 172.18 | 13.59 |
Nov | 163.29 | 154.86 | 167.40 | 7.49 |
Dec | 154.67 | 150.40 | 163.95 | 8.26 |
BioNTech information and performance
AN DER GOLDGRUBE 12, MAINZ, DE
Market capitalization of the BioNTech SE is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BNTX shares in the company outstanding by the market price of one share.
EBITDA of BioNTech is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
BioNTech (BNTX) stock dividend
BioNTech last paid dividends on 06/02/2022. The next scheduled payment will be on 06/17/2022. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about BioNTech Stock)
Should I Buy BioNTech Shares in 2025 year?
Does BioNTech pay dividends?
Which economic sector do BioNTech's shares belong to?
Which other securities belong to the same sector as BioNTech's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.